Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISA 101

Next Previous
X
Search
Drug Profile

ISA 101

Alternative Names: HPV-16; HPV-SLP; HPV16-SLP; Human papilloma virus type 16 E6/E7 synthetic long peptides - ISA Pharmaceuticals; ISA 101b; ISA-101; ISA-HPV; ISA-HPV-01; ISA-HPV-SLP®; SLP-HPV-01

Latest Information Update: 21 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ISA Pharmaceuticals
  • Developer Bristol-Myers Squibb; ISA Pharmaceuticals; Regeneron Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vulvar intraepithelial neoplasia; Cervical cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Head and neck cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer; Vulvar intraepithelial neoplasia
  • Phase I/II Anal intraepithelial neoplasia

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase-II trial in cervical cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Adverse events and efficacy data from a phase II trial in Oropharyngeal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 29 May 2024 Regeneron Pharmaceuticals completes a phase-II trials in Cervical cancer (Combination therapy, Second-line therapy or greater, Recurrent, Metastatic disease) in Russia, Spain, South Korea, Netherlands, Italy, Brazil, Belgium (SC) (NCT04646005)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top